TRIPLE-1-INC.
4.2.2020 12:02:06 CET | Business Wire | Press release
TRIPLE-1 Inc. (Headquarters: Hakata-ku, Fukuoka-shi, Fukuoka; Representative Director CEO: Takuya Yamaguchi; Henceforth: TRIPLE-1) has announced two new products: The ASIC "KAMIKAZE Ⅱ" for Bitcoin mining that uses a 7 nm process made by TSMC, and the AI processor "GOKU" for deep learning that uses the world's leading 5 nm process.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200204005385/en/
--- Overview
In the "cryptocurrency mining market" that is driving the miniaturization of semiconductor processes in recent years, an extremely severe business model has been formed that directly links the power performance of semiconductors used for mining with mining proceeds. Starting in February 2017, TRIPLE-1 has been using core know-how involving the designability for cutting edge processes, the optimization of electrical consumption, and the improvement of the yield rate that have been fostered from the development of ASIC (application-specific integrated circuits) for cryptocurrency mining. Development has started on both "KAMIKAZE Ⅱ", the latest high-performance ASIC for Bitcoin mining that uses a 7 nm process made by TSMC, and the AI processor "GOKU" for deep learning that uses the world's leading 5 nm process.
--- Next generation 7 nm Bitcoin mining ASIC "KAMIKAZE Ⅱ" – That design completed
By making use of the know-how fostered from the initial "KAMIKAZE" model, the design for the next generation model "KAMIKAZE Ⅱ" has been finalized. After tape outing to TSMC and the prototype has been inspected, we will start mass production from 2021.
Additionally, we have started to offer reference boards and reference designs for the first "KAMIKAZE" mining machine model, the system that can provide smoother installation support is ready.
< Feature > ASIC Boost is built-in, improving the mining efficiency rapidly
By loading the custom algorithm "ASIC Boost" that improves mining efficiency (it was not loaded on to the first “KAMIKAZE” model), a more highly efficient mining environment is provided. Additionally, by supporting ultra-low voltage drive (supplied voltage 0.2x V), we anticipate a drastic reduction in electrical consumption.
KAMIKAZE / KAMIKAZE Ⅱ Performance specifications comparison
|
KAMIKAZE |
KAMIKAZE Ⅱ |
Process |
TSMC 7 nm |
TSMC 7 nm improved process |
Die size |
3.5 × 3.9 mm |
3.0 × 9.0 mm |
Package |
7 × 7 mm FC-BGA |
7 × 12 mm FC-LGA |
Input voltage |
0.3 V or less |
Drives at a lower voltage than KAMIKAZE |
Power consumption |
1.2 W / chip |
6.7 W / chip |
Hash rate |
23 GHs / chip |
240 GHs / chip |
Electrical efficiency |
52 W / THs |
28 W / THs |
ASIC Boost |
None |
Supported |
*KAMIKAZE: Chip actual value, KAMIKAZEⅡ: Design target
--- New challenges, enter the AI market
In recent years, various companies have entered the AI chip market, including not only giant IT companies but also fast-growing start-ups in China. As competition for edge AI chip development intensifies, oligopoly supply by several major companies continues in the deep learning AI processor market. Currently there are no mass-produced chips smaller than 12 nm process.
On the other hand, the electrical consumption of data centers is expected to excess 10% of the entire world's electrical energy by 2030. TRIPLE-1 believe that AI processors for deep learning need not only high "computing power" to learn and process a huge amount of data, but also a severe viewpoint on "power consumption" from the viewpoint of energy conservation and cost reduction.
Therefore TRIPLE-1 has launched the project to develop "GOKU", an ultra-low power consumption dedicated deep learning AI processor using the world's most advanced 5nm process, utilizing our unique Low power / High performance technology and design know-how in the most advanced processes.
--- "GOKU", an AI processor for deep learning with the world's leading 5 nm process
The first stage prototype has been completed, and we are inspecting the performance. Realizing the mass production in 2021, we will complete the prototypes closer to mass-produced products within 2020. It will be sold to the equipment and devices manufacturers for data servers or deep learning centers around the world, and we have already begun to discuss with multiple companies.
< Feature > Using the world's leading 5 nm process, it has 10 times higher power efficiency than conventional
Our goal is to reduce power consumption by 1/10 of the equivalent performance compared to conventional products (process: 12 nm), and its feature is low-voltage operation that is inconceivable with existing products.
< Feature > Design to connect multiple calculation units
Like the structure of the human brain, where synapses connect neurons in a complex manner, great amount and very complex inter-core communication is important for deep learning AI processors.
Utilizing the unique circuit design technology of "GOKU", which arranges many small arithmetic units on one large die as much as possible, it is designed to secure the communication (interconnect) band between the arithmetic units as much as possible.
It has been designed to get closer to the human brain.
< Reference > GOKU performance table (Design target)
Process |
5 nm |
Power consumption |
100 W |
Peak performance (half-precision) |
1 PFLOPS (1,000 TFLOPS) |
Electrical efficiency (half-precision) |
10 TFLOPS / W |
--- TRIPLE-1 outline
Company Name: TRIPLE-1, Inc.
Corporate Headquarter:
7F IT Bldg.Ⅱ,1-14-20 Hakataeki-Higashi, Hakata-ku Fukuoka-shi, Fukuoka, Japan
Representatives: Representative Director CEO Takuya Yamaguchi
The capital: 3662 million 895 thousand and 398 yen (including the capital reserve)
View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005385/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
